Fair Value Measurements - Fair Value of Assets and Liabilities on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands		Dec. 31, 2017	Mar. 31, 2017
ASSETS
Cash and cash equivalents	[1]	$ 23,359	$ 37,673
Restricted cash and cash equivalents		3,393	4,916
Total		26,752	42,589
LIABILITIES
Contingent consideration related to acquisitions	[2]		18,817
Total			18,817
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
ASSETS
Cash and cash equivalents	[1]	23,359	37,673
Restricted cash and cash equivalents		3,393	4,916
Total		26,752	42,589
LIABILITIES
Contingent consideration related to acquisitions	[2]		0
Total			0
Significant Other Observable Inputs (Level 2) [Member]
ASSETS
Cash and cash equivalents	[1]	0	0
Restricted cash and cash equivalents		0	0
Total		0	0
LIABILITIES
Contingent consideration related to acquisitions	[2]		18,817
Total			18,817
Unobservable Inputs (Level 3) [Member]
ASSETS
Cash and cash equivalents	[1]	0	0
Restricted cash and cash equivalents		0	0
Total		$ 0	0
LIABILITIES
Contingent consideration related to acquisitions	[2]		0
Total			$ 0

[1] Cash equivalents consist primarily of money market funds.

[2] The contingent consideration liability as of March 31, 2017 relates to the acquisition of HealthFusion, which was settled during the quarter ended June 30, 2017. The measurement period of the contingent consideration liability ended on December 31, 2016, and thus the actual revenue achievement rate was utilized to compute the ending contingent consideration liability as of March 31, 2017. Accordingly, the contingent consideration liability was reflected under a Level 2 valuation hierarchy because the fair value was determined based on other significant observable inputs.